Cynthia Epperson
Concepts (557)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenstrual Syndrome | 18 | 2023 | 34 | 5.080 |
Why?
| | Pregnancy Complications | 21 | 2018 | 525 | 4.050 |
Why?
| | Depression, Postpartum | 18 | 2022 | 132 | 3.650 |
Why?
| | Premenstrual Dysphoric Disorder | 13 | 2024 | 19 | 3.470 |
Why?
| | Stress, Psychological | 14 | 2024 | 1097 | 3.470 |
Why?
| | Menopause | 13 | 2023 | 319 | 3.140 |
Why?
| | Sex Characteristics | 14 | 2024 | 763 | 3.010 |
Why?
| | Depressive Disorder, Major | 15 | 2024 | 362 | 2.890 |
Why?
| | Mental Disorders | 13 | 2025 | 1070 | 2.190 |
Why?
| | Depression | 20 | 2023 | 1397 | 2.120 |
Why?
| | Brain | 22 | 2024 | 2664 | 1.990 |
Why?
| | Gonadal Steroid Hormones | 6 | 2018 | 140 | 1.930 |
Why?
| | Mood Disorders | 7 | 2020 | 129 | 1.920 |
Why?
| | Executive Function | 9 | 2024 | 440 | 1.910 |
Why?
| | Lisdexamfetamine Dimesylate | 3 | 2024 | 8 | 1.890 |
Why?
| | gamma-Aminobutyric Acid | 11 | 2023 | 198 | 1.830 |
Why?
| | Female | 146 | 2025 | 72816 | 1.740 |
Why?
| | Prefrontal Cortex | 7 | 2019 | 304 | 1.710 |
Why?
| | Cross-Over Studies | 10 | 2024 | 562 | 1.610 |
Why?
| | Reflex, Startle | 3 | 2022 | 65 | 1.600 |
Why?
| | Depressive Disorder | 8 | 2017 | 379 | 1.570 |
Why?
| | Hydrocortisone | 5 | 2024 | 322 | 1.540 |
Why?
| | Perimenopause | 4 | 2023 | 63 | 1.530 |
Why?
| | Sex Factors | 16 | 2024 | 2064 | 1.480 |
Why?
| | Antidepressive Agents | 13 | 2024 | 235 | 1.480 |
Why?
| | Prenatal Exposure Delayed Effects | 5 | 2019 | 605 | 1.400 |
Why?
| | Hypothalamo-Hypophyseal System | 8 | 2024 | 197 | 1.360 |
Why?
| | Menstrual Cycle | 10 | 2025 | 133 | 1.350 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2022 | 178 | 1.350 |
Why?
| | Serotonin | 9 | 2024 | 323 | 1.340 |
Why?
| | Humans | 162 | 2025 | 136803 | 1.330 |
Why?
| | Cognition | 9 | 2023 | 1146 | 1.330 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2023 | 165 | 1.310 |
Why?
| | Memory, Short-Term | 6 | 2020 | 249 | 1.270 |
Why?
| | Pregnancy | 38 | 2025 | 6729 | 1.260 |
Why?
| | Biomedical Research | 3 | 2021 | 688 | 1.230 |
Why?
| | Stress, Physiological | 5 | 2024 | 441 | 1.210 |
Why?
| | Tryptophan | 7 | 2020 | 183 | 1.190 |
Why?
| | Anxiety | 12 | 2022 | 1031 | 1.180 |
Why?
| | Pituitary-Adrenal System | 6 | 2024 | 162 | 1.170 |
Why?
| | Central Nervous System Stimulants | 3 | 2024 | 161 | 1.070 |
Why?
| | Psychotherapy | 8 | 2018 | 167 | 1.060 |
Why?
| | Salpingo-oophorectomy | 2 | 2024 | 18 | 1.060 |
Why?
| | Adult | 76 | 2025 | 37643 | 1.050 |
Why?
| | Lower Urinary Tract Symptoms | 4 | 2020 | 60 | 1.050 |
Why?
| | Estradiol | 12 | 2023 | 518 | 1.020 |
Why?
| | Longevity | 2 | 2019 | 165 | 0.990 |
Why?
| | Progesterone | 9 | 2023 | 254 | 0.970 |
Why?
| | Postmenopause | 4 | 2023 | 365 | 0.950 |
Why?
| | Stress Disorders, Post-Traumatic | 5 | 2019 | 842 | 0.950 |
Why?
| | Transgender Persons | 2 | 2018 | 182 | 0.930 |
Why?
| | Emigrants and Immigrants | 2 | 2024 | 138 | 0.930 |
Why?
| | Smoking Cessation | 4 | 2022 | 436 | 0.930 |
Why?
| | Sertraline | 6 | 2024 | 29 | 0.930 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2018 | 69 | 0.900 |
Why?
| | Child Abuse | 3 | 2020 | 528 | 0.890 |
Why?
| | Double-Blind Method | 15 | 2024 | 1982 | 0.880 |
Why?
| | Smartphone | 1 | 2025 | 92 | 0.870 |
Why?
| | Mothers | 4 | 2024 | 752 | 0.850 |
Why?
| | Glutamic Acid | 6 | 2024 | 246 | 0.840 |
Why?
| | C-Reactive Protein | 2 | 2023 | 408 | 0.830 |
Why?
| | Saliva | 2 | 2024 | 242 | 0.820 |
Why?
| | Psychiatric Status Rating Scales | 12 | 2022 | 547 | 0.820 |
Why?
| | Urinalysis | 1 | 2023 | 77 | 0.810 |
Why?
| | Magnetic Resonance Imaging | 12 | 2024 | 3556 | 0.810 |
Why?
| | Gender Identity | 3 | 2018 | 124 | 0.800 |
Why?
| | Positron-Emission Tomography | 3 | 2020 | 293 | 0.790 |
Why?
| | Ethics Committees, Research | 2 | 2020 | 41 | 0.790 |
Why?
| | Emotions | 6 | 2023 | 545 | 0.790 |
Why?
| | Obsessive-Compulsive Disorder | 8 | 2010 | 46 | 0.780 |
Why?
| | Nicotine | 4 | 2024 | 334 | 0.780 |
Why?
| | Pregnanolone | 6 | 2023 | 37 | 0.750 |
Why?
| | Psychopharmacology | 1 | 2021 | 9 | 0.740 |
Why?
| | Transsexualism | 2 | 2018 | 19 | 0.730 |
Why?
| | Middle Aged | 44 | 2025 | 33239 | 0.730 |
Why?
| | Prenatal Diagnosis | 1 | 2023 | 200 | 0.720 |
Why?
| | Affect | 6 | 2023 | 292 | 0.690 |
Why?
| | Cognition Disorders | 3 | 2017 | 495 | 0.680 |
Why?
| | Estrogens | 4 | 2020 | 368 | 0.680 |
Why?
| | Therapy, Computer-Assisted | 3 | 2017 | 62 | 0.670 |
Why?
| | Tobacco Use Disorder | 1 | 2022 | 251 | 0.670 |
Why?
| | Mental Health | 4 | 2024 | 716 | 0.660 |
Why?
| | Luteal Phase | 6 | 2024 | 45 | 0.660 |
Why?
| | Attention | 2 | 2015 | 426 | 0.650 |
Why?
| | Life Change Events | 3 | 2017 | 151 | 0.640 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 6 | 2015 | 243 | 0.630 |
Why?
| | Smoking | 5 | 2022 | 1620 | 0.630 |
Why?
| | Sleep Wake Disorders | 1 | 2023 | 283 | 0.630 |
Why?
| | Health Resources | 1 | 2020 | 119 | 0.620 |
Why?
| | Surveys and Questionnaires | 14 | 2025 | 5744 | 0.620 |
Why?
| | Young Adult | 23 | 2024 | 13129 | 0.610 |
Why?
| | Interdisciplinary Research | 1 | 2019 | 27 | 0.600 |
Why?
| | Male | 48 | 2025 | 67330 | 0.590 |
Why?
| | Ovarian Neoplasms | 2 | 2024 | 562 | 0.580 |
Why?
| | Acoustic Stimulation | 2 | 2018 | 316 | 0.580 |
Why?
| | Cost of Illness | 1 | 2020 | 302 | 0.570 |
Why?
| | Patient Dropouts | 1 | 2018 | 67 | 0.550 |
Why?
| | Inflammation | 4 | 2024 | 2835 | 0.540 |
Why?
| | Puerperal Disorders | 2 | 2010 | 32 | 0.540 |
Why?
| | Resilience, Psychological | 1 | 2019 | 128 | 0.540 |
Why?
| | Immune System | 1 | 2018 | 177 | 0.540 |
Why?
| | Urinary Bladder, Overactive | 2 | 2019 | 22 | 0.530 |
Why?
| | Premature Birth | 4 | 2017 | 331 | 0.530 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2024 | 128 | 0.500 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 610 | 0.480 |
Why?
| | Occipital Lobe | 5 | 2006 | 22 | 0.480 |
Why?
| | Dementia | 2 | 2016 | 256 | 0.480 |
Why?
| | Cigarette Smoking | 1 | 2017 | 101 | 0.470 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2014 | 131 | 0.470 |
Why?
| | Treatment Outcome | 22 | 2022 | 10748 | 0.460 |
Why?
| | Postpartum Period | 6 | 2022 | 338 | 0.450 |
Why?
| | Monoamine Oxidase | 1 | 2014 | 30 | 0.450 |
Why?
| | Outpatients | 1 | 2018 | 393 | 0.440 |
Why?
| | Research Design | 4 | 2024 | 1127 | 0.440 |
Why?
| | Bipolar Disorder | 3 | 2011 | 264 | 0.430 |
Why?
| | Cytokines | 2 | 2019 | 2084 | 0.430 |
Why?
| | Adolescent | 19 | 2024 | 21385 | 0.430 |
Why?
| | Platelet Aggregation | 1 | 2014 | 100 | 0.430 |
Why?
| | Patient Acceptance of Health Care | 3 | 2017 | 805 | 0.420 |
Why?
| | Patient Compliance | 1 | 2018 | 577 | 0.420 |
Why?
| | Neuroimaging | 5 | 2024 | 259 | 0.420 |
Why?
| | Antipsychotic Agents | 4 | 2006 | 193 | 0.420 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2013 | 15 | 0.420 |
Why?
| | Memory | 2 | 2013 | 248 | 0.410 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 752 | 0.400 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 576 | 0.400 |
Why?
| | Quality of Life | 4 | 2019 | 2878 | 0.400 |
Why?
| | Estrus | 1 | 2012 | 11 | 0.400 |
Why?
| | Libido | 2 | 2023 | 23 | 0.390 |
Why?
| | Neurotransmitter Agents | 2 | 2018 | 82 | 0.390 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2012 | 22 | 0.390 |
Why?
| | Amines | 1 | 2012 | 40 | 0.390 |
Why?
| | Sexual Maturation | 1 | 2012 | 55 | 0.390 |
Why?
| | Seasonal Affective Disorder | 2 | 2011 | 11 | 0.380 |
Why?
| | Spermatozoa | 2 | 2024 | 94 | 0.380 |
Why?
| | Steroids | 2 | 2018 | 167 | 0.370 |
Why?
| | Smokers | 2 | 2022 | 145 | 0.370 |
Why?
| | Neuropsychological Tests | 7 | 2020 | 1022 | 0.370 |
Why?
| | Propylamines | 1 | 2011 | 10 | 0.360 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2011 | 17 | 0.360 |
Why?
| | White Matter | 2 | 2024 | 145 | 0.360 |
Why?
| | Fluoxetine | 5 | 2006 | 54 | 0.350 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 698 | 0.340 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 412 | 0.340 |
Why?
| | Reproductive History | 1 | 2010 | 17 | 0.340 |
Why?
| | Blood Platelets | 2 | 2004 | 407 | 0.340 |
Why?
| | Memory Disorders | 1 | 2011 | 161 | 0.330 |
Why?
| | Trichotillomania | 3 | 1999 | 5 | 0.320 |
Why?
| | Pregnanes | 2 | 2006 | 3 | 0.320 |
Why?
| | Aging | 3 | 2015 | 1864 | 0.310 |
Why?
| | Animals | 15 | 2024 | 36850 | 0.310 |
Why?
| | Naltrexone | 1 | 2010 | 97 | 0.310 |
Why?
| | Behavior, Animal | 1 | 2012 | 497 | 0.310 |
Why?
| | United States | 12 | 2025 | 14691 | 0.300 |
Why?
| | Narcotic Antagonists | 1 | 2010 | 179 | 0.290 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2184 | 0.290 |
Why?
| | Hormone Replacement Therapy | 2 | 2018 | 96 | 0.290 |
Why?
| | Oxygen | 1 | 2013 | 930 | 0.290 |
Why?
| | beta-Cyclodextrins | 2 | 2018 | 28 | 0.280 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 926 | 0.280 |
Why?
| | Women's Health | 3 | 2017 | 369 | 0.280 |
Why?
| | Anxiety Disorders | 3 | 2021 | 374 | 0.280 |
Why?
| | Prevalence | 7 | 2022 | 2710 | 0.270 |
Why?
| | Telemedicine | 3 | 2025 | 852 | 0.270 |
Why?
| | Pilot Projects | 6 | 2024 | 1693 | 0.270 |
Why?
| | Phototherapy | 2 | 2004 | 38 | 0.260 |
Why?
| | Interleukin-6 | 2 | 2023 | 778 | 0.260 |
Why?
| | Reproducibility of Results | 5 | 2021 | 3265 | 0.260 |
Why?
| | Breast Feeding | 4 | 2014 | 439 | 0.260 |
Why?
| | Mental Health Services | 2 | 2025 | 416 | 0.260 |
Why?
| | Oxytocin | 2 | 1996 | 51 | 0.250 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2023 | 1242 | 0.250 |
Why?
| | Prolactin | 1 | 2006 | 97 | 0.240 |
Why?
| | Abortion, Legal | 1 | 2025 | 22 | 0.240 |
Why?
| | Self Report | 3 | 2020 | 822 | 0.240 |
Why?
| | Risk Factors | 8 | 2019 | 10332 | 0.240 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2018 | 139 | 0.230 |
Why?
| | Maternal Behavior | 2 | 2016 | 78 | 0.230 |
Why?
| | Gestational Age | 2 | 2023 | 902 | 0.230 |
Why?
| | Sperm Motility | 1 | 2024 | 32 | 0.230 |
Why?
| | Risperidone | 3 | 2000 | 29 | 0.220 |
Why?
| | Puberty | 1 | 2006 | 146 | 0.220 |
Why?
| | Cross-Sectional Studies | 6 | 2023 | 5424 | 0.220 |
Why?
| | HIV Infections | 1 | 2019 | 2828 | 0.220 |
Why?
| | Latin America | 1 | 2024 | 93 | 0.220 |
Why?
| | Neuronal Plasticity | 2 | 2024 | 290 | 0.220 |
Why?
| | Career Mobility | 1 | 2024 | 68 | 0.210 |
Why?
| | Epilepsy | 1 | 2008 | 331 | 0.210 |
Why?
| | Mexico | 1 | 2024 | 225 | 0.210 |
Why?
| | Aged | 12 | 2020 | 23808 | 0.210 |
Why?
| | Abortion, Induced | 1 | 2025 | 103 | 0.210 |
Why?
| | Awards and Prizes | 1 | 2024 | 67 | 0.210 |
Why?
| | Nocturia | 2 | 2020 | 8 | 0.210 |
Why?
| | Medicaid | 2 | 2018 | 433 | 0.210 |
Why?
| | Ovary | 1 | 2025 | 221 | 0.210 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2829 | 0.210 |
Why?
| | Health Services Accessibility | 2 | 2025 | 978 | 0.210 |
Why?
| | Prenatal Care | 2 | 2017 | 288 | 0.200 |
Why?
| | Hospitalization | 1 | 2013 | 2184 | 0.200 |
Why?
| | Mother-Child Relations | 1 | 2024 | 137 | 0.200 |
Why?
| | Socioeconomic Factors | 4 | 2017 | 1282 | 0.200 |
Why?
| | Pirenzepine | 2 | 1999 | 7 | 0.200 |
Why?
| | Acoustics | 1 | 2022 | 42 | 0.200 |
Why?
| | Cohort Studies | 6 | 2024 | 5704 | 0.200 |
Why?
| | Health Status | 2 | 2020 | 788 | 0.190 |
Why?
| | Serotonin Antagonists | 3 | 2000 | 32 | 0.190 |
Why?
| | Maternal Exposure | 1 | 2004 | 188 | 0.190 |
Why?
| | Medically Unexplained Symptoms | 1 | 2022 | 5 | 0.190 |
Why?
| | Premenopause | 1 | 2023 | 131 | 0.190 |
Why?
| | Comorbidity | 6 | 2018 | 1614 | 0.190 |
Why?
| | Milk, Human | 1 | 2003 | 158 | 0.190 |
Why?
| | Urination | 1 | 2022 | 45 | 0.190 |
Why?
| | Sexual Behavior | 2 | 2023 | 484 | 0.180 |
Why?
| | Administration, Cutaneous | 3 | 2011 | 128 | 0.180 |
Why?
| | Child | 8 | 2020 | 21819 | 0.180 |
Why?
| | Consensus | 2 | 2016 | 678 | 0.180 |
Why?
| | Psychiatry | 1 | 2024 | 180 | 0.180 |
Why?
| | Health Priorities | 1 | 2021 | 44 | 0.180 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.180 |
Why?
| | Sex Offenses | 1 | 2024 | 193 | 0.180 |
Why?
| | Faculty, Medical | 1 | 2024 | 283 | 0.180 |
Why?
| | Urinary Bladder | 2 | 2020 | 183 | 0.180 |
Why?
| | Pennsylvania | 2 | 2018 | 116 | 0.180 |
Why?
| | Norpregnadienes | 1 | 2020 | 7 | 0.180 |
Why?
| | RNA, Small Untranslated | 1 | 2020 | 16 | 0.170 |
Why?
| | Reward | 1 | 2023 | 244 | 0.170 |
Why?
| | Animal Care Committees | 1 | 2020 | 6 | 0.170 |
Why?
| | Fatigue | 1 | 2022 | 327 | 0.170 |
Why?
| | Epigenesis, Genetic | 3 | 2020 | 657 | 0.170 |
Why?
| | Cues | 1 | 2022 | 313 | 0.160 |
Why?
| | BRCA2 Protein | 1 | 2020 | 63 | 0.160 |
Why?
| | BRCA1 Protein | 1 | 2020 | 76 | 0.160 |
Why?
| | Contraception | 1 | 2022 | 159 | 0.160 |
Why?
| | Nerve Net | 2 | 2020 | 256 | 0.160 |
Why?
| | Hypogonadism | 1 | 2020 | 88 | 0.160 |
Why?
| | Menstruation | 2 | 2012 | 43 | 0.160 |
Why?
| | Ovariectomy | 1 | 2020 | 152 | 0.160 |
Why?
| | Sex Distribution | 1 | 2020 | 374 | 0.160 |
Why?
| | Administration, Oral | 2 | 2012 | 813 | 0.160 |
Why?
| | Infant | 5 | 2024 | 9395 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5106 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 213 | 0.160 |
Why?
| | Cerebral Cortex | 1 | 2002 | 433 | 0.150 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.150 |
Why?
| | GABA Agonists | 1 | 2018 | 19 | 0.150 |
Why?
| | Propensity Score | 1 | 2020 | 289 | 0.150 |
Why?
| | History, 20th Century | 1 | 2020 | 324 | 0.150 |
Why?
| | Receptors, GABA | 1 | 2018 | 14 | 0.150 |
Why?
| | Protons | 2 | 2012 | 89 | 0.150 |
Why?
| | Occupations | 1 | 2018 | 48 | 0.150 |
Why?
| | Gender Dysphoria | 1 | 2018 | 19 | 0.150 |
Why?
| | Benzodiazepines | 3 | 2014 | 153 | 0.150 |
Why?
| | Psychophysiology | 1 | 2018 | 13 | 0.150 |
Why?
| | N-Acetylglucosaminyltransferases | 1 | 2018 | 22 | 0.150 |
Why?
| | Neurobiology | 1 | 2018 | 15 | 0.150 |
Why?
| | 1-Naphthylamine | 2 | 1997 | 2 | 0.150 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2018 | 98 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 806 | 0.140 |
Why?
| | Cause of Death | 1 | 2020 | 430 | 0.140 |
Why?
| | Pandemics | 2 | 2024 | 1616 | 0.140 |
Why?
| | Mitochondria | 1 | 2024 | 946 | 0.140 |
Why?
| | Obstetric Labor Complications | 1 | 2017 | 34 | 0.140 |
Why?
| | Sleep | 1 | 2024 | 753 | 0.140 |
Why?
| | Glutamine | 2 | 2016 | 103 | 0.140 |
Why?
| | Melatonin | 2 | 2011 | 150 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 385 | 0.130 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 190 | 0.130 |
Why?
| | Child of Impaired Parents | 1 | 2017 | 41 | 0.130 |
Why?
| | Monitoring, Ambulatory | 1 | 2017 | 87 | 0.130 |
Why?
| | Population Surveillance | 1 | 2020 | 474 | 0.130 |
Why?
| | Family Conflict | 1 | 2017 | 41 | 0.130 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2016 | 3 | 0.130 |
Why?
| | Self Concept | 1 | 2018 | 249 | 0.130 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2016 | 12 | 0.130 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 55 | 0.130 |
Why?
| | Domestic Violence | 1 | 2017 | 53 | 0.130 |
Why?
| | Interleukin-1beta | 1 | 2018 | 371 | 0.130 |
Why?
| | Radionuclide Imaging | 1 | 2016 | 118 | 0.130 |
Why?
| | Perinatal Care | 1 | 2017 | 56 | 0.130 |
Why?
| | Cross-Cultural Comparison | 1 | 2016 | 87 | 0.130 |
Why?
| | Adrenal Glands | 1 | 2016 | 78 | 0.130 |
Why?
| | Child Abuse, Sexual | 1 | 2017 | 88 | 0.130 |
Why?
| | Precision Medicine | 1 | 2020 | 426 | 0.130 |
Why?
| | Carcinoma, Renal Cell | 1 | 2019 | 215 | 0.130 |
Why?
| | Ecosystem | 1 | 2021 | 594 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 549 | 0.120 |
Why?
| | Patient Care Management | 1 | 2016 | 56 | 0.120 |
Why?
| | Standard of Care | 1 | 2016 | 73 | 0.120 |
Why?
| | Physicians | 1 | 2024 | 907 | 0.120 |
Why?
| | Infant, Newborn | 6 | 2014 | 6032 | 0.120 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2018 | 176 | 0.120 |
Why?
| | Feces | 1 | 2018 | 481 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2022 | 15510 | 0.120 |
Why?
| | Fear | 1 | 2018 | 338 | 0.110 |
Why?
| | Patient Preference | 1 | 2017 | 190 | 0.110 |
Why?
| | Brain Mapping | 4 | 2020 | 504 | 0.110 |
Why?
| | Data Collection | 2 | 2024 | 668 | 0.110 |
Why?
| | Placebos | 2 | 2013 | 199 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 182 | 0.110 |
Why?
| | Astronauts | 1 | 2014 | 27 | 0.110 |
Why?
| | Testosterone | 1 | 2018 | 401 | 0.110 |
Why?
| | Behavioral Research | 1 | 2014 | 36 | 0.110 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 284 | 0.110 |
Why?
| | Fetal Development | 2 | 2018 | 296 | 0.110 |
Why?
| | Feasibility Studies | 2 | 2017 | 951 | 0.110 |
Why?
| | Transcriptome | 1 | 2020 | 969 | 0.110 |
Why?
| | Obesity | 2 | 2018 | 2982 | 0.110 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 401 | 0.110 |
Why?
| | Poverty | 1 | 2018 | 520 | 0.110 |
Why?
| | Urban Population | 1 | 2017 | 476 | 0.110 |
Why?
| | Space Flight | 1 | 2014 | 87 | 0.110 |
Why?
| | Gyrus Cinguli | 1 | 2014 | 86 | 0.110 |
Why?
| | Drug Therapy, Combination | 5 | 2006 | 1062 | 0.110 |
Why?
| | Mental Recall | 1 | 2015 | 201 | 0.110 |
Why?
| | Ultrasonography, Doppler | 1 | 2014 | 123 | 0.110 |
Why?
| | Anisotropy | 2 | 2024 | 79 | 0.100 |
Why?
| | Patient Satisfaction | 2 | 2014 | 656 | 0.100 |
Why?
| | Psychotherapy, Brief | 1 | 2013 | 34 | 0.100 |
Why?
| | Acute Disease | 2 | 2020 | 1007 | 0.100 |
Why?
| | Rodentia | 1 | 2013 | 57 | 0.100 |
Why?
| | Behavior | 2 | 2020 | 90 | 0.100 |
Why?
| | Brain Chemistry | 2 | 2007 | 116 | 0.100 |
Why?
| | Frontal Lobe | 1 | 2014 | 149 | 0.100 |
Why?
| | Brachial Artery | 1 | 2014 | 201 | 0.100 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 79 | 0.100 |
Why?
| | Histones | 1 | 2018 | 636 | 0.100 |
Why?
| | Weight Loss | 1 | 2018 | 776 | 0.100 |
Why?
| | Infant, Low Birth Weight | 1 | 2013 | 140 | 0.100 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 412 | 0.100 |
Why?
| | Circadian Rhythm | 3 | 2014 | 469 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2822 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 820 | 0.090 |
Why?
| | Delirium | 1 | 2013 | 89 | 0.090 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 587 | 0.090 |
Why?
| | Placenta | 1 | 2018 | 749 | 0.090 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2011 | 6 | 0.090 |
Why?
| | Prescription Drugs | 1 | 2013 | 109 | 0.090 |
Why?
| | Disease Management | 1 | 2015 | 624 | 0.090 |
Why?
| | Patients | 1 | 2013 | 174 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1481 | 0.090 |
Why?
| | Peripartum Period | 1 | 2011 | 17 | 0.090 |
Why?
| | Projection | 1 | 2010 | 3 | 0.090 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 14 | 0.090 |
Why?
| | Psychoanalytic Therapy | 1 | 2010 | 10 | 0.090 |
Why?
| | Body Weight | 2 | 2018 | 985 | 0.090 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2010 | 20 | 0.090 |
Why?
| | Patient Education as Topic | 2 | 2010 | 761 | 0.090 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 652 | 0.090 |
Why?
| | Vasodilation | 1 | 2014 | 496 | 0.090 |
Why?
| | Diet | 1 | 2018 | 1274 | 0.090 |
Why?
| | Alzheimer Disease | 1 | 2016 | 559 | 0.090 |
Why?
| | Object Attachment | 1 | 2010 | 42 | 0.080 |
Why?
| | Psychomotor Performance | 2 | 2011 | 309 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2016 | 3540 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2012 | 215 | 0.080 |
Why?
| | Apoptotic Protease-Activating Factor 1 | 1 | 2010 | 2 | 0.080 |
Why?
| | Menarche | 1 | 2010 | 60 | 0.080 |
Why?
| | Boston | 2 | 2020 | 91 | 0.080 |
Why?
| | Parturition | 1 | 2010 | 71 | 0.080 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4282 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2010 | 143 | 0.080 |
Why?
| | Fluvoxamine | 3 | 1999 | 17 | 0.080 |
Why?
| | Antimanic Agents | 1 | 2009 | 17 | 0.080 |
Why?
| | Follicular Phase | 2 | 2014 | 39 | 0.080 |
Why?
| | Seasons | 1 | 2011 | 544 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3947 | 0.080 |
Why?
| | Nitric Oxide | 1 | 2014 | 915 | 0.080 |
Why?
| | Estrogen Replacement Therapy | 2 | 2015 | 146 | 0.080 |
Why?
| | Triazines | 1 | 2009 | 43 | 0.070 |
Why?
| | Age of Onset | 1 | 2010 | 518 | 0.070 |
Why?
| | Alleles | 2 | 2010 | 890 | 0.070 |
Why?
| | Time Factors | 3 | 2018 | 6809 | 0.070 |
Why?
| | Logistic Models | 1 | 2013 | 2067 | 0.070 |
Why?
| | Recurrence | 2 | 2013 | 1055 | 0.070 |
Why?
| | Critical Care | 1 | 2013 | 583 | 0.070 |
Why?
| | Aspartic Acid | 2 | 2005 | 79 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1076 | 0.070 |
Why?
| | Fetal Growth Retardation | 1 | 2013 | 564 | 0.070 |
Why?
| | Odds Ratio | 1 | 2010 | 1066 | 0.070 |
Why?
| | Amino Acids | 1 | 2011 | 497 | 0.070 |
Why?
| | Azetidines | 1 | 2007 | 43 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7593 | 0.070 |
Why?
| | Interviews as Topic | 1 | 2010 | 772 | 0.070 |
Why?
| | Drug Combinations | 2 | 2018 | 343 | 0.070 |
Why?
| | Administration, Intranasal | 2 | 1996 | 89 | 0.060 |
Why?
| | Medication Adherence | 1 | 2010 | 468 | 0.060 |
Why?
| | Gonadal Disorders | 1 | 2006 | 1 | 0.060 |
Why?
| | Arousal | 1 | 2007 | 155 | 0.060 |
Why?
| | Dehydroepiandrosterone | 1 | 2006 | 51 | 0.060 |
Why?
| | Verbal Learning | 1 | 2006 | 60 | 0.060 |
Why?
| | Photic Stimulation | 1 | 2007 | 241 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1044 | 0.060 |
Why?
| | Hormones | 1 | 2006 | 142 | 0.060 |
Why?
| | Receptors, Nicotinic | 1 | 2007 | 334 | 0.060 |
Why?
| | Semen Analysis | 1 | 2024 | 14 | 0.060 |
Why?
| | Epididymis | 1 | 2024 | 12 | 0.060 |
Why?
| | Health Surveys | 2 | 2019 | 513 | 0.060 |
Why?
| | Cotinine | 1 | 2005 | 77 | 0.060 |
Why?
| | Visual Perception | 1 | 2006 | 160 | 0.060 |
Why?
| | Cell Respiration | 1 | 2024 | 102 | 0.060 |
Why?
| | Limbic System | 1 | 2024 | 47 | 0.060 |
Why?
| | Suicidal Ideation | 2 | 2022 | 522 | 0.050 |
Why?
| | Androsterone | 1 | 2023 | 3 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1772 | 0.050 |
Why?
| | Electronics | 1 | 2024 | 75 | 0.050 |
Why?
| | Ketanserin | 1 | 2003 | 12 | 0.050 |
Why?
| | Pyridines | 1 | 2007 | 506 | 0.050 |
Why?
| | Half-Life | 1 | 2003 | 164 | 0.050 |
Why?
| | Receptors, Serotonin | 1 | 2003 | 34 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2024 | 162 | 0.050 |
Why?
| | Chronic Disease | 2 | 2020 | 1786 | 0.050 |
Why?
| | Technology | 1 | 2024 | 95 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2004 | 307 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2489 | 0.050 |
Why?
| | Facial Expression | 1 | 2023 | 72 | 0.050 |
Why?
| | Heterosexuality | 1 | 2023 | 43 | 0.050 |
Why?
| | Biomarkers | 2 | 2024 | 4145 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1572 | 0.050 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 145 | 0.050 |
Why?
| | Child, Preschool | 1 | 2017 | 10997 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 327 | 0.050 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2021 | 19 | 0.050 |
Why?
| | Washington | 1 | 2022 | 154 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 80 | 0.050 |
Why?
| | Synaptic Transmission | 2 | 2020 | 289 | 0.040 |
Why?
| | Biology | 1 | 2022 | 88 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2020 | 78 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 785 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5750 | 0.040 |
Why?
| | alpha-Methyltyrosine | 1 | 1999 | 2 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 464 | 0.040 |
Why?
| | Preliminary Data | 1 | 2019 | 11 | 0.040 |
Why?
| | Dysuria | 1 | 2019 | 1 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2020 | 138 | 0.040 |
Why?
| | Teaching Materials | 1 | 1999 | 23 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 105 | 0.040 |
Why?
| | Catecholamines | 1 | 1999 | 98 | 0.040 |
Why?
| | Alcoholism | 1 | 2005 | 804 | 0.040 |
Why?
| | Risk Assessment | 3 | 2019 | 3434 | 0.040 |
Why?
| | Urinary Incontinence | 1 | 2019 | 66 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 349 | 0.040 |
Why?
| | Mice | 3 | 2024 | 17759 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2018 | 18 | 0.040 |
Why?
| | Philadelphia | 1 | 2018 | 49 | 0.040 |
Why?
| | Personality Inventory | 2 | 2013 | 140 | 0.040 |
Why?
| | Neural Pathways | 1 | 2020 | 295 | 0.040 |
Why?
| | Restraint, Physical | 1 | 2018 | 72 | 0.040 |
Why?
| | Histone Code | 1 | 2018 | 34 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 169 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2018 | 207 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 622 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2024 | 1094 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 114 | 0.040 |
Why?
| | Control Groups | 1 | 2017 | 11 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 452 | 0.040 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2014 | 75 | 0.040 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 36 | 0.040 |
Why?
| | Reproduction | 1 | 1999 | 204 | 0.030 |
Why?
| | Placebo Effect | 1 | 2017 | 25 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 389 | 0.030 |
Why?
| | Health Personnel | 1 | 2024 | 701 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 232 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1998 | 297 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1999 | 345 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2006 | 1069 | 0.030 |
Why?
| | Anhedonia | 1 | 2017 | 13 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 686 | 0.030 |
Why?
| | Patient Health Questionnaire | 1 | 2017 | 37 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 1998 | 162 | 0.030 |
Why?
| | Pulse | 1 | 1996 | 23 | 0.030 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2016 | 32 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2018 | 218 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 888 | 0.030 |
Why?
| | Workplace | 1 | 2018 | 258 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 579 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 412 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 283 | 0.030 |
Why?
| | Trophoblasts | 1 | 2018 | 199 | 0.030 |
Why?
| | Reference Standards | 1 | 2016 | 186 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 839 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Observer Variation | 1 | 2016 | 341 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1321 | 0.030 |
Why?
| | Organ Size | 1 | 2016 | 477 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1262 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 500 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.030 |
Why?
| | Corticosterone | 1 | 2016 | 236 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.030 |
Why?
| | Ambulatory Care | 1 | 1999 | 539 | 0.030 |
Why?
| | Connecticut | 1 | 2014 | 27 | 0.030 |
Why?
| | Aerospace Medicine | 1 | 2014 | 29 | 0.030 |
Why?
| | Hot Flashes | 1 | 2015 | 87 | 0.030 |
Why?
| | Weightlessness | 1 | 2014 | 45 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2052 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 1998 | 595 | 0.030 |
Why?
| | Choline | 2 | 2005 | 127 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 75 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 172 | 0.030 |
Why?
| | MicroRNAs | 1 | 2020 | 692 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1998 | 769 | 0.030 |
Why?
| | Multimedia | 1 | 2013 | 10 | 0.030 |
Why?
| | Parity | 1 | 2014 | 125 | 0.030 |
Why?
| | Suicide, Attempted | 1 | 2017 | 373 | 0.030 |
Why?
| | San Francisco | 1 | 2013 | 52 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 183 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2014 | 143 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1914 | 0.020 |
Why?
| | Group Processes | 1 | 2013 | 62 | 0.020 |
Why?
| | Attitude | 1 | 2014 | 259 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3286 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 549 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4013 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 616 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2014 | 559 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 62 | 0.020 |
Why?
| | Blood Pressure | 1 | 1996 | 1774 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 720 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 514 | 0.020 |
Why?
| | Dopamine Antagonists | 2 | 2000 | 27 | 0.020 |
Why?
| | Internet | 1 | 2013 | 647 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1267 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 766 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 975 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3189 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 656 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1462 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 844 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2123 | 0.020 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 80 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2007 | 330 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2007 | 177 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2179 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2518 | 0.020 |
Why?
| | Creatine | 1 | 2005 | 57 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7573 | 0.010 |
Why?
| | Fluorine Radioisotopes | 1 | 2003 | 12 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 2003 | 66 | 0.010 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2003 | 20 | 0.010 |
Why?
| | Pyramidal Cells | 1 | 2003 | 74 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2831 | 0.010 |
Why?
| | Tics | 1 | 2000 | 2 | 0.010 |
Why?
| | Schizotypal Personality Disorder | 1 | 2000 | 10 | 0.010 |
Why?
| | Models, Neurological | 1 | 2002 | 242 | 0.010 |
Why?
| | Treatment Failure | 1 | 1999 | 354 | 0.010 |
Why?
| | Clomipramine | 1 | 1996 | 2 | 0.010 |
Why?
| | Buspirone | 1 | 1996 | 3 | 0.010 |
Why?
| | Clonazepam | 1 | 1996 | 5 | 0.010 |
Why?
| | Paroxetine | 1 | 1996 | 11 | 0.010 |
Why?
| | Fenfluramine | 1 | 1996 | 14 | 0.010 |
Why?
| | Lithium | 1 | 1996 | 43 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1316 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1996 | 105 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1996 | 206 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1998 | 659 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 407 | 0.010 |
Why?
|
|
Epperson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|